Brookman, Laurence, Rolan, P E, Benjamin, I S, Palmer, K R, Wyld, P J, Lloyd, P, Flesch, Gerard J.P., Waldmeier, Felix, Sioufi, A and Mullins, F (1997) Pharmacokinetics of valsartan in patients with liver disease. Clinical pharmacology and therapeutics, 62 (3). pp. 272-278. ISSN 0009-9236

Abstract

Valsartan (CGP 48933), an orally active angiotensin II antagonist, is eliminated mainly by hepatic clearance. To characterize the compound(s) excreted in the bile, biliary excretion of valsartan was investigated by collection of bile after an intravenous dose of valsartan. In addition, to determine the exposure to valsartan when liver function is impaired, a pharmacokinetic study (open, single dose) was performed in patients with mild and moderate impairment of liver function.

Item Type:	Article
Related URLs:	http://www.ncbi.nlm.nih.gov/sites/entrez...
Related URLs:	http://www.ncbi.nlm.nih.gov/sites/entrez...
Date Deposited:	31 Jan 2012 00:45
Last Modified:	01 Feb 2013 00:45
URI:	https://oak.novartis.com/id/eprint/6540